<DOC>
	<DOCNO>NCT01488838</DOCNO>
	<brief_summary>A Randomized Phase II study Adjuvant Concurrent Radiation Chemotherapy versus Radiation alone Resected High-Risk Malignant Salivary Gland Tumors</brief_summary>
	<brief_title>A Randomized Phase II Study Adjuvant Concurrent Radiation Chemotherapy Versus Radiation Alone Resected High-Risk Malignant Salivary Gland Tumors</brief_title>
	<detailed_description />
	<mesh_term>Salivary Gland Neoplasms</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>1 . Pathologically proven diagnosis malignant major salivary gland tumor follow histologic subtypes : high grade mucoepidermoid carcinoma , salivary duct carcinoma high grade adenocarcinoma ; 2 . Surgical resection curative intent within 8 week prior registration ; 3 . Pathologic stage T34 N13 T12 , N0 close ( ≤1mm ) microscopically positive surgical margin ( AJCC , 7th ed . ; see Appendix IV ) ; patient must free distant metastasis base upon follow minimum diagnostic workup : 4 . Zubrod Performance Status 01 ; 3.1.5 Age ≥ 18 ; 3.1.6 CBC/differential obtain within 4 week prior registration , adequate bone marrow function 3.1.7 Adequate renal hepatic function within 4 week prior registration 3.1.8 Negative serum pregnancy test within 2 week prior registration woman childbearing potential ; 3.1.9 Women childbearing potential male participant sexually active must practice adequate contraception treatment 6 week follow treatment . 3.1.10 Patients must deem able comply treatment plan followup schedule . 3.2.1 Patients residual macroscopic disease surgery ; 3.2.2 Patients salivary gland malignancy originate minor salivary gland ; 3.2.3 Patients histology high grade mucoepidermoid carcinoma , high grade adenocarcinoma salivary duct carcinoma ; 3.2.4 Prior invasive malignancy ( except nonmelanomatous skin cancer ) unless disease free minimum 3 year ( example , carcinoma situ breast , oral cavity , cervix permissible ) ; 3.2.5 Prior systemic chemotherapy radiation therapy salivary gland malignancy ; note prior chemotherapy different cancer allowable ; 3.2.6 Prior radiotherapy region study cancer would result overlap radiation therapy field ; 3.2.7 Severe , active comorbidity , define follow : 3.2.7.1 Unstable angina and/or congestive heart failure require hospitalization within last 6 month ; 3.2.7.2 Transmural myocardial infarction within last 6 month ; 3.2.7.3 Acute bacterial fungal infection require intravenous antibiotic time registration ; 3.2.7.4 Chronic Obstructive Pulmonary Disease exacerbation respiratory illness require hospitalization preclude study therapy time registration ; 3.2.7.5 Hepatic insufficiency result clinical jaundice and/or coagulation defect ; Note , however , coagulation parameter require entry protocol . 3.2.7.6 Acquired Immune Deficiency Syndrome ( AIDS ) 3.2.7.7 Preexisting ≥ grade 2 neuropathy ; 3.2.7.8 Prior organ transplant . 3.2.8 Pregnancy woman childbearing potential men sexually active willing/able use medically acceptable form contraception ; exclusion necessary ; 3.2.9 Significant preexist hearing loss , define patient treat physician .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>December 2011</verification_date>
</DOC>